Podcasts about mounjaro

Siga nosso canal de CORTES: https://www.youtube.com/@IconografiadaHistoria-cortesAJUDE-NOS A MANTER O CANAL ICONOGRAFIA DA HISTÓRIA: Considere apoiar nosso trabalho, participar de sorteios e garantir acesso ao nosso grupo de Whatsapp exclusivo: https://bit.ly/apoiaoidhSe preferir, faz um PIX: https://bit.ly/PIXidhSiga ICONOGRAFIA DA HISTÓRIA em todas as redes: https://linktr.ee/iconografiadahistoriaoficialSiga o JOEL PAVIOTTI: https://bit.ly/joelpaviottiApresentação: Joel PaviottiTexto e roteirização: Adriana de PaulaRevisão: Adriana de PaulaCâmera e produção: Fernando ZenerattoEdição: Eduardo GoesDireção: Fernando Zeneratto / Joel Paviotti

The Transformative Truth About Weight Loss Meds: Reclaiming Health, Not Just Shedding Pounds  Today, we're examining one of the most talked-about topics in health and fitness right now: weight loss medications.  Yep, we're talking Ozempic, Wegovy, and Mounjaro.If you've opened a magazine, scrolled social media, or just had coffee with friends lately, you've probably heard about these meds. Maybe you're taking one. Maybe you're considering it. Or maybe you're wondering if they're all hype.  Well, today we're going to cut through the noise and talk about what really matters: how these medications work, whatthey do for your health, and how to make them work for you, especially if you're 40 or older and serious about long-term wellness.

Ozempic. Wegovy. Mounjaro. If you've ever found yourself wondering, “Should I try one?”—this episode is for you.Roughly 12% of Americans have tried a weight loss drug, yet up to 85% stop within two years. Most regain the weight, and many feel worse than before. So why do these drugs seem so promising—and why don't they work long-term?Today you will learn…- How GLP-1 drugs actually work - The dark side of GLP-1s that no one mentions- What happens when you stop taking weight loss medications - The sustainable alternative to healing food noise

Friends, let's talk about the "poopy" subject nobody wants to discuss! My colonoscopy prep was a complete rollercoaster experience, and I believe my GLP-1 medication was the reason. If you're on Ozempic, Wegovy, or Mounjaro and suffer from constipation, you must watch this before your procedure! I'm sharing the extended prep tips and advice you need to discuss with your doctor.Don't let this happen to you! Share this with someone you love and join us in our journey toward a healthy, wealthy, and happy life!Support the show✨ Stay Connected & Level Up Your Life! ✨

In this episode, you will learn:What are peptides? The basic science of these "small proteins" and how they signal cells to function.GLP-1s Explained: How drugs like Ozempic and Mounjaro were originally developed for diabetes but have gained popularity for weight loss.The Big Picture: Peptides are used for more than just weight loss—Dr. Jones discusses their use in migraines, bone building, and studies for ALS and MS.The Weight Loss Surge: Why obesity and its link to chronic diseases (diabetes, hypertension, high cholesterol) is fueling interest in these drugs.The Critical Component: Why a GLP-1 shot is not enough—the medication must be combined with good nutrition, exercise, and psychological health for lasting success.Protein is Key: The importance of adequate protein intake and strength training to maintain muscle mass and prevent hair loss associated with rapid weight loss.The Inflammation Link: How GLP-1s can decrease inflammation (like high cortisol) which often causes stubborn abdominal fat and joint pain.Dispelling Myths: Separating real side effects (like minor hypoglycemia) from media fear-mongering (like blindness), and understanding that hair loss is often due to rapid weight loss, not the drug itself.Next Steps: Where to start if you are interested in peptide therapy and the importance of a consult with a pharmacist.Resources Mentioned:Your Health Wellness Team: Contact the team to schedule a consultation on weight loss goals and peptide therapy. www.YourHealth.Org

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

OZEMPIC, WEGOVY & MOUNJARO : ce que les LABOS NE VOUS DISENT PAS (et pourquoi ça change tout) Ozempic, Wegovy ou Mounjaro, vous les connaissez, ce sont ces médicaments initialement prévu pour lutter contre le diabète qui sont aujourd'hui utilisés et prescrit contre l'obésité et le surpoids. Quels sont les effets de l'Ozempic, du Wegovy et du Mounjaro et comment fonctionent-ils ? La perte de poids est-elle suffisante et durable ? Quel est le coût de ces médicaments qui font maigrir et faut(-il suivre ce traitement à vie ? Maigrir sans effort, c'est le rêve de beaucoup. Mais pour une véritable perte de poids efficace et durable, nou sallons voir que ces produits ne sont ni de vrais produits minceur ni des produits miracle.

Medications such as Ozempic, Mounjaro and more have been popular in the media in recent years, but how can they affect menopause? In this episode, Adele unpacks the truth behind the buzz surrounding GLP-1 medications. Are they really miracle weight loss drugs for those in menopause? Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102   Holst, J. J., & Madsbad, S. (2016). Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases, 12(6), 1236–1242. https://doi.org/10.1016/j.soard.2016.02.033 ____________ Check out Adele's FREE symptom assessment here: https://adelejohnstoncoaching.com/free-copy-of-our-symptom-assessment/ 12 Minute Breathwork Method: https://adelejohnstoncoaching.com/breathwork/ The Menopause Cheat Sheet: https://docs.google.com/document/d/1ka-fN6J5DJW2J3IE0Qa80zFCKFXmTs4srlnlXYBf-gA/edit?usp=sharing If you want a chat for your future success, fuel yourself here: https://calendly.com/adelejohnston/successchat Download Adele's Journey Journal here : https://adelejohnstoncoaching.com/my-journey-journal/ Enquire about 121 coaching here : https://docs.google.com/forms/d/e/1FAIpQLSfw6vrmKPE7A1eYDKQJiR9No7ZDdpfq-grBdKYjZSR-vl0Qag/viewform For extra support: Support@adelejohnstoncoaching.com ____________ From your host : Adele Johnston I'm Adele Johnston, a certified nutritionist and positive psychology coach, passionate about helping women improve their menopause health and reclaim who you are without menopause taking over. This is a time in your life where you get to feel vibrant, sexy and reclaim you again! I'm proud to work with women like you and have created a very successful proven Reclaiming You 3 STEP PROCESS to help you take back control of your body during your menopause. For more details : https://adelejohnstoncoaching.com/ To get Adele's FREE 3-step Menopause Weight Loss Guide: https://adelejohnstoncoaching.com/menopause-weight-loss-guide/

Send us a text When doctors recommend weight loss, they describe the supposed benefits but remain silent about the harms—reduced metabolism, increased appetite, hormonal disruption, eating disorders, and profound mental health impacts. This ethical failure extends beyond outdated diet advice to newer interventions like GLP-1 medications, where we celebrate short-term metabolic improvements while ignoring gastrointestinal distress, financial burden, social isolation, and unknown long-term consequences. In this episode, Asher challenges the dangerous assumption that fat people should suffer to become thinner, exposing how this narrative serves the weight loss industry's profits while treating fat bodies as unworthy of basic ethical consideration in healthcare. Got a question for the next podcast? Let me know! Connect With Me WEEKLY NEWSLETTER: Get a free script when you sign up THE WEIGHTING ROOM: A community where authenticity thrives and every voice matters The CONSULTING ROOM: Get answers to all your medical questions via DM or Voice Note PLUS access to my entire library of paid resources CONSULTATION: For the ultimate transformation in your healthcare journe THE WEIGH FORWARD: For people who are being denied surgery because of their weight FREE GUIDES:Evidence-based, not diet nonsense Find me on Instagram, YouTube, and LinkedIn.

After taking some much-needed time off before, during, and after our family cruise, I'm finally back behind the mic — and whew, it's been a minute! In this episode, I'm catching you up on life, how hard it can be to get back into your rhythm, and the lessons I learned along the way.This isn't just a vacation recap. It's a reminder that life is happening right now. You can't wait until you lose the weight or have it all together to make memories. From cruise chaos to core memories, I'm sharing how “someday” never comes, why you should take the trip, and what going with the flow taught me about self-acceptance and joy.Plus, I'll share a few of my favorite Amazon outfit finds and cruise must haves that made the trip easier, cuter, and a little more glam (even in mom mode).

Welcome back to The Weight Loss Collab! In today's episode, bariatric surgeon and obesity medicine expert Dr. Dovec is diving deep into the world of GLP-1 medications—those popular injectables like Ozempic, Wegovy, Zepbound, and Mounjaro that everyone's been talking about. Whether you're fresh out of bariatric surgery, struggling with weight plateaus, have a lower or higher BMI, or you're just curious if these meds might be right for you, Dr. Dovec breaks down exactly how GLP-1s work, who benefits most, potential side effects, and how to personalize your treatment for the best results. Plus, she compared options like phentermine and Contrave, and gives real talk about surgery versus medication. If you're looking for up-to-date, honest guidance on weight loss medications and a supportive community cheering you on, this episode is packed with insights and actionable advice!

In this jam-packed episode, Haylee and Jess break down everything you actually need to know about GLP-1 medications, from how they work to how they impact your gut, appetite, and metabolism.

Recentemente, a ANVISA aprovou a indicação do medicamento Mounjaro para o tratamento da apnéia do sono. Essa indicação soma-se às já existentes: diabetes tipo 2, obesidade, redução do risco cardiovascular e redução na progressão da doença renal do diabetes. Em breve, é provável que vejamos indicações formais para gordura no fígado e ovários policísticos. Isso significa que uma extensa gama de especialidades médicas passarão a prescrever os injetáveis rotineiramente - e isso requer alguns cuidados.Links relacionados:Anvisa aprova uso de Mounjaro para tratamento da apneia do sonoTirzepatide for the Treatment of Obstructive Sleep Apnea and ObesityOvários policísticos melhoram com Low CarbEpisódio Extra – Série Além Da Moda – Episódio 9: Resistência À Insulina, Síndrome Metabólica E DiabetesEstamos no Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Souto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sari Fontana⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Para ser avisado sobre cada novo episódio e receber os links das matérias mencionadas e as referências bibliográficas por e-mail, cadastre-se gratuitamente em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drsouto.com.br/podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira seu livro - UMA DIETA ALÉM DA MODA: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (também na versão Kindle)"Dance of the Sugar Plum Fairy"Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0⁠⁠⁠⁠⁠⁠⁠⁠http://creativecommons.org/licenses/by/3.0/⁠⁠

We meet Dr Ibrahim  an NHS doctor who has been open about his lifelong struggle with weight and his decision to start the Mounjaro (GLP-1) jab. In this episode, he shares what it's really like to be both a doctor and a patient using the medication — the stigma, the questions he's asked most often, and how he approaches safety and long-term use with honesty and care. We talk about the realities behind the “golden dose,” the risks of unverified syringes sold online, and what patients should understand about side effects like pancreatitis and gallstones. Dr Ibrahim also explains why every weight-loss journey needs a plan for maintenance, how microdosing works in theory versus practice, and how he's rebuilt a healthier mindset through running, patience, and consistency. It's a clear-headed, compassionate look at the medical and emotional sides of GLP-1 treatment — perfect for anyone considering Mounjaro or wanting to hear from a doctor who truly understands it from experience. Podcast Timeline: 00:00:00 Welcome back — why Claire wanted a medical guest to talk about Mounjaro 00:01:00 Life update — caring for her dad & using hypnosis to cope with overwhelm 00:03:00 Mindset when motivation feels low — permission to pause and reset 00:04:00 The moment of confidence: buying size-16 jeans after a year of change 00:06:00 Introducing Dr Ibrahim — NHS doctor and GP trainee using Mounjaro himself 00:07:00 Lifelong weight struggles & the mindset behind finally trying the jab 00:09:00 The stigma and judgment professionals still face when choosing the jab 00:10:00 Top questions about Mounjaro — safety, side effects & realistic expectations 00:12:00 Why safety and mindset matter more than cost when starting GLP-1 medication 00:15:00 The “golden dose” myth — medical risks and the importance of proper guidance 00:19:00 Understanding side effects: pancreatitis, gallstones & being medically screened 00:25:00 Maintenance mindset — preparing for long-term habits beyond the jab 00:28:00 Microdosing and tapering — what's known, what's not, and why patience matters 00:33:00 Rebuilding a healthy relationship with food — hypnosis, habits & healing 00:39:00 Mindset shift: running for mental space, not punishment  

In this week's episode, I'm joined by emotional and disordered eating specialist Lisa Unger for an honest look at the rise of weight loss injections and the impact they can have. We explore how weight, food and wellbeing are deeply tied to our emotions, self esteem and body image.Lisa explains why medications like Ozempic can help some people, especially those with Type 2 diabetes, yet rarely create lasting change unless we also address the underlying drivers of our eating behaviours.We touch on the emotional layers that so often sit beneath overeating, why focusing only on food keeps us stuck, and how nurturing body esteem, self trust and emotional resilience leads to sustainable, long term change.Find out more about Lisa here; https://lisaunger.co.uk

Inflammation, Cortisol and HIIT & Weight loss plateaus on MounjaroMessage me here with any topics you would like covered.

In this episode of The Body Pod, we sit down with Dr. Spencer Nadolsky — The GLP-1 Doc to uncover the truth about GLP-1 medications like Ozempic, Wegovy, and Mounjaro, and what they really mean for women's health, hormones, and sustainable weight loss.We dig into the real science behind appetite, metabolism, and obesity, and why weight gain isn't a failure of willpower but a matter of biology and hormones — especially for women in perimenopause and menopause. Dr. Nadolsky explains the myths around diet culture, Big Pharma, and compounded GLP-1 medications, plus how the medical system often overlooks women struggling with weight, fatigue, and hormonal changes. Whether you're curious about GLP-1 drugs, navigating menopause weight gain, or frustrated by conflicting weight loss advice, this conversation will leave you informed, empowered, and hopeful about your health journey.

GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® are changing the weight-loss landscape, but there's more to the journey than watching the scale move. In this episode, we break down 4 essential considerations everyone on a GLP-1 should know.With Mindy's science-based and trustworthy expertise, these are the considerations to protect your health during and after medication use:1. Preventing Lean Muscle Mass loss and Osteoporosis2. Managing GI Issues3. Preventing nutrient deficiencies 4. Build Healthy HabitsThis episode is supportive, judgment-free, and packed with actionable takeaways. Whether you're on a GLP-1, considering one, or supporting someone who is, this conversation will leave you feeling empowered and informed. References:Wong, ND, et al. US Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2023Wong, ND, et al.  Population Eligibility and Estimated Impact of Semaglutide.  Cardiovasc Drug Ther. 2024 Chakhtoura, M., et al. Pharmacotherapy of obesity: EClinicalMedicine, 2023 Volek J, et al. Nutritional Considerations During Major Weight Loss.  Curr Nutr Rep. 2024Meslon E, et al.  What is the pipeline for future medications in obesity? Nature. 2024Martin CK, et al.  Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.  Nat Med. 2025Dilly A, et al.  Characteristics and food consumption for current, previous, and potential consumers of GLP-1s.  Food Quality and Preference.  2025;129;105507We are so glad you are here. Want to stay in touch?Follow us on social media: Sweat and Laughter podcast - @sweat.and.laughter.podcast Mindy - @strongover40_dietitian Cheryl - @training.with.cheryl Mindy & Cheryl - @mcfitadventures Email us: mcfitadventures@gmail.com Thank you so much for listening to Sweat & Laughter. M & C

In this episode of Finding Genius, host Richard Jacobs welcomes Dr. Sofia Din, anti-aging and longevity expert, for a deep and insightful conversation about GLP-1 agonists — the groundbreaking class of medications transforming the way we think about health, beauty, and aging. Dr. Din breaks down what GLP-1 agonists (like Ozempic, Wegovy, and Mounjaro) really do inside the body — beyond weight loss — exploring their potential role in metabolic health, skin rejuvenation, and longevity.

GLP-1 Agonists (Glucagon Like Peptide 1 Agonists) such as Mounjaro and Wegovy are becoming more widely used, here we cover examples of GLP1 Agonists, mechanism of action, as well as GLP1 agonist side effects. PDFs Available at: www.rhesusmedicine.com Consider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What are GLP-1 Agonists? 0:23 GLP-1 Agonist Mechanism of Action1:35 GLP-1 Agonist Indications & Uses2:37 GLP-1 Agonist Examples 4:05 GLP-1 Agonist Side EffectsPlease remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. ReferencesManne-Goehler, J., Franco, J., 2025. Side effects of GLP-1 receptor agonists. BMJ, 390:r1606. [online] Available at: https://www.bmj.com/content/390/bmj.r1606.full. (bmj.com)Collins, L., 2024. Glucagon-like peptide-1 (GLP-1) receptor agonists. StatPearls. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/. (NCBI)Andreasen, C.R., Andersen, A., Knop, F.K. & Vilsbøll, T., 2021. How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 10(7). [online] Available at: https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml. (ec.bioscientifica.com)Diabetes UK, 2025. GLP-1 agonists – tablets and medication. [online] Available at: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1. (Diabetes UK)

In this episode, I'm joined by Claire Buckley, who opens up about her lifelong struggle with food, emotional eating, and the constant “food noise” that shaped so much of her life. Claire talks about how she first realised her relationship with food felt different from those around her, the frustration of seeking help through traditional weight loss groups, and the deeper emotional cycle that kept her feeling stuck. She shares honestly about panic attacks, shame, and the sense of failure that came with every new attempt — and how finding the right support, along with her experience using Mounjaro, has helped her quiet the noise and begin to rebuild trust with herself. It's a powerful, relatable conversation about self-awareness, compassion, and what it really means to find peace with food. Timestamps 00:00 Welcome back + introducing guest Claire Buckley 01:00 Life update — hospital visits, house move & a wake-up call on health 03:00 How the jab helped reduce cravings during an emotional week 04:00 Introducing Claire's story — trauma, fibromyalgia & chronic pain 05:00 Hypnosis in action — 15 minutes to pain-free after 10 years 06:00 Claire's TikTok community & breaking stigma around the jab 07:00 Living with constant “food noise” and never feeling full 10:00 Anxiety, panic attacks & barriers to NHS weight support 12:00 Emotional eating — subconscious habits and binge cycles 14:00 Weight-loss groups, frustration, and the diet rebound trap 17:00 Finding balance — calorie tracking and gentle flexibility 18:00 Understanding fullness cues — the hypnosis perspective 21:00 Rock-bottom moment and discovering Mounjaro 23:00 First jab experience — fear of needles and relief 24:00 The next morning — quiet mind and reduced food noise 26:00 Eating intentionally — planning, protein & control 27:00 Retraining the brain — new relationship with hunger 28:00 Host reflection — mindset shifts and health transformation 29:00 Life after the jab — maintaining results and balance 30:00 Outro — follow Claire on TikTok & subscribe for Part 2

Welcome to Ozempic Weightloss Unlocked, where we break down the most up-to-date stories in the world of Ozempic, from healthcare breakthroughs to the cultural waves reshaping how we think about weight loss. I am glad you are here.Let us dig into one of the biggest developments making headlines: a national Gallup survey just revealed that the United States is seeing a real decrease in adult obesity rates for the first time in years. This is not just a blip. Experts are linking the trend to the rapid rise in use of GLP-1 medications like Ozempic. According to Healthline and CBS News, the number of Americans using these injectables for weight loss has more than doubled in just the past year, with about twelve percent now reporting current use. Women are leading the charge in use and have seen slightly bigger drops in obesity rates compared to men.The story does not stop with adults. Think Global Health points out that Ozempic and similar drugs are being prescribed more frequently to adolescents, with use in children and teens increasing by nearly six hundred percent over the last five years. This surge follows Food and Drug Administration approval for ages twelve and up, but experts caution that pediatric guidelines and global access remain uneven.Back to the grown-ups: age seems to be a key factor. According to Gallup's analysis, adults between forty and sixty-four years old are using these medications most and have had the greatest reductions in obesity rates. Meanwhile, older Americans show higher rates of using these drugs but do not see as big an impact on their obesity numbers.Now, what is happening in the body when someone takes Ozempic? These medications work by mimicking hormones in the gut that help control appetite. They make you feel full longer, reduce hunger, and even curb cravings for fatty foods. The result is, as Medical News Today explains, many people lose meaningful weight — and maintain improvements in blood sugar, blood pressure, and cholesterol levels.But here is something that might surprise you. According to a large international study led by University College London and shared in Science Daily, Ozempic does not just help with weight. It reduces the risk of heart attack and stroke by about twenty percent, even for people who do not lose a lot of weight while on the drug. Researchers saw these heart benefits for people across a range of body types. The study found that a reduction in waist size did explain some of the improvement in heart health, but a full two-thirds of the benefits seemed unrelated to weight loss alone, which suggests Ozempic may support heart health through other mechanisms.Let us talk long-term results, because listeners want to know what happens after the initial weight loss. New research shared in the Cochrane Database of Systematic Reviews and reported by major health outlets compared Ozempic to other leading medications. Drugs like Mounjaro helped patients lose up to sixteen percent of their body weight over twelve to eighteen months and keep it off for as long as three and a half years. For Ozempic, the sustained weight loss averaged eleven percent over sixteen months, with benefits lasting for around two years. All of these drugs outperformed older medications in long-term trials.However, experts say it is important to be aware of the whole picture. Like all medications, Ozempic and similar drugs come with side effects. The most common are digestive issues like nausea, constipation, or diarrhea, along with headaches and abdominal pain. Fatigue can occur too. And doctors stress that weight management with these drugs is not quick or effortless. It is a long-term process that requires commitment to healthy habits in diet and movement for the results to last.One final thought: as usage spreads, voices like the Pew Research Center note that most Americans now see these medications as a good option for people with true weight-related health issues. Still, a sizeable stigma remains about using them for non-medical reasons.Thank you for tuning in to Ozempic Weightloss Unlocked, where the science and stories making headlines come straight to your headphones. Do not forget to subscribe for all the latest news on Ozempic and its impact on health, lifestyles, and beyond.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reaching $10 billion in a single quarter. This success can be attributed to Lilly's innovative direct-to-consumer sales strategy, which exemplifies how modern marketing approaches can overcome traditional market barriers. Additionally, Eli Lilly's partnership with Walmart to expand access to Zepbound through retail pharmacy pickups exemplifies a strategic approach to enhancing patient access to crucial medications. By leveraging Walmart's extensive retail network, this collaboration facilitates easier access to obesity treatments—a significant public health challenge—enhancing both patient convenience and broadening market reach for Lilly's products. These achievements not only highlight the potential of strategic marketing but also underscore a growing demand for effective obesity treatments within the pharmaceutical industry.In another exciting development, Alnylam Pharmaceuticals has reported impressive sales figures for Amvuttra, a treatment for transthyretin amyloid cardiomyopathy. Surpassing analysts' expectations, this success signals a growing market for treatments targeting rare diseases and emphasizes the importance of strategic market expansion to reach underserved patient populations.Meanwhile, Bristol Myers Squibb's anticipated schizophrenia treatment, Cobenfy, has experienced a lukewarm market entry. While meeting initial expectations in its first year, it has yet to create the breakthrough impact investors anticipated. This situation highlights the challenges even well-hyped pharmaceuticals face upon launch and underscores the need for continuous strategic planning to ensure market penetration and sustained growth.A surprising development in mergers and acquisitions comes from Novo Nordisk's $6.5 billion counteroffer to acquire Metsera, an obesity biotech initially targeted by Pfizer. This aggressive move reflects intense competition in the obesity drug market and illustrates the high stakes involved in acquiring promising biotech assets that could potentially transform treatment paradigms for chronic conditions like obesity.The vaccine industry is navigating its own set of challenges with declining sales across the board. However, Merck's adult pneumococcal vaccine Capvaxive has shown promising initial sales figures. As the first pneumococcal vaccine specifically designed for adults, Capvaxive indicates a potential niche market that Merck could successfully capture.On the regulatory front, significant measures are being taken by the FDA to boost biosimilar availability against drug pricing pressures. New draft guidance aims to eliminate clinical testing requirements for biosimilars and categorize all approved biosimilars as "interchangeable." This initiative could significantly reduce biologic medicine costs post-patent expiration and increase competition in the market, potentially making essential medications more accessible to patients. Additionally, the FDA is proposing streamlined biosimilar approval pathways aimed at reducing overall bio-drug costs—a welcome move reflecting concerted efforts to make essential medications more affordable and accessible globally.Argenx has reported positive trial results for Vyvgart in treating generalized myasthenia gravis (gMG), highlighting its commitment to addressing unmet needs within this patient population. These findings could expand treatment options for gMG patients who have been previously overlooked in thSupport the show

Jim Cramer and David Faber explored what to make of earnings from three of the Magnificent 7 mega-caps: Meta shares tumbled and Microsoft's stock fell as AI spending increases overshadowed quarterly beats — while shares of Google parent Alphabet surged on better-than-expected results, fueled by strength in the cloud. Starbucks CEO Brian Niccol joined the program to discuss his company's results and turnaround plan. Eli Lilly CEO David Ricks spoke to Jim and David about his company's earnings and what's next for its Mounjaro weight loss drug. Also in focus: The meeting between Presidents Trump and Xi, Novo Nordisk-Pfizer bidding war, Chipotle plunges, Comcast's earnings message.Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the first time in a while, obesity numbers are dropping in the U.S.  Some believe it is due to the use of popular GLP-1s such as Mounjaro and Ozempic, but while those drugs may be making people thinner, diabetes rates are on the rise. So what gives? Greg and Holly discuss.

A gain in same-store sales wasn't enough to reel investors back into Starbucks (SBUX). Diane King Hall says a lack of outlook had many investors scratching their heads. Eli Lilly (LLY) rallied after showing strength in its Mounjaro and Zepbound weight-loss drugs. Estée Lauder (EL) posted a profit that Diane King Hall calls a "sigh of relief" for investors.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In this episode, we take a closer look at tirzepatide, a type 2 diabetes medication also used to help with weight loss. Postmenopause weight gain can be a normal part of aging, and there are some questions about whether medications like tirzepatide could be useful and safe for postmenopausal women. Host Aaron Lohr talks with Maria Daniela Hurtado Andrade, MD, PhD, assistant professor of medicine at Mayo Clinic Florida, and Regina Castaneda, MD, a research fellow at Mayo Clinic College of Medicine & Science. They presented an abstract at ENDO 2025 titled, “One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women With and Without Hormone Therapy.” Show notes are available at https://www.endocrine.org/podcast/enp105 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

In the past week, Ozempic and its role in weight loss have remained at the forefront of health news as public discussion deepens about its efficacy, risks, and the pronounced cultural shift these medications have sparked. Ozempic, known generically as semaglutide and originally developed as a diabetes treatment, is a GLP-1 receptor agonist that works by slowing gastric emptying and suppressing appetite, making users feel full longer and reducing overall food intake. This mechanism has made it exceptionally popular for weight loss, particularly as social media, celebrity testimonials, and off-label prescribing converged to push demand higher than ever before. Market analysts note that by late 2025, the majority of new Ozempic prescriptions are for weight management rather than diabetes, marking a significant departure from its intended clinical use and raising concerns about access for patients with diabetes who genuinely need the drug.The transformation of Ozempic from a type two diabetes solution to a cultural touchstone for cosmetic weight loss is partly credited to the attention from high-profile figures such as Oprah Winfrey. This week, Oprah appeared at the American Ballet Theatre Fall Gala in New York City, her appearance turning heads and fueling conversation due to her notably slimmed-down figure. Reports from Hello Magazine describe Oprah's confidence on the red carpet as she showcased a dramatic weight loss of more than fifty pounds, achieved through a combination of lifestyle modifications and, crucially, the assistance of a GLP-1 medication. At age seventy-one, Oprah has spoken openly this week about the lifelong struggle with her weight and the social stigma that accompanied it. She told People Magazine that after decades of blame and shame, both from external commentators and herself, the availability of medically approved weight loss medications feels to her like both relief and redemption. She described how the weight loss journey for her began in earnest following knee surgery in 2021, when she started an active regimen of hiking and physical fitness, complemented eventually by her doctor's prescription for semaglutide.Oprah acknowledged grappling with the stigma tied to weight loss medications, initially resisting the idea out of concern it may appear she was taking an easy way out. However, recent interviews reveal she has set aside any feelings of shame, now describing the medication as a legitimate tool—one that enabled her to shed long-standing weight and maintain her health, not just for cosmetic reasons but as a genuine medical necessity. Though some have criticized the trend of using medications such as Ozempic, Wegovy, and Mounjaro for cosmetic weight management, Oprah's insights over the week have reframed the conversation for many listeners. She emphasized that the ability to access medication for weight issues in her lifetime is not something to hide but a breakthrough for many who have suffered physically and emotionally from long-term obesity and its attendant health risks.The clinical conversation around Ozempic has also intensified this week. Drug safety concerns, including the risk of gastrointestinal complications such as pancreatitis and gastroparesis, have been spotlighted by healthcare outlets and legal analysts. Regulatory agencies continue to grapple with the surge in off-label use among populations that may not fully meet the criteria for medical obesity, often motivated by the relentless demands of modern aesthetics rather than underlying health needs. Medical professionals report increasing pressure from patients desperate to access these drugs after seeing dramatic transformations online, which has complicated the careful balancing act between ensuring proper care and responding to unprecedented demand.Critically, the public discourse, amplified by Oprah's willingness to openly discuss her experience, is moving the conversation from that of quick fixes and shame to one of nuanced understanding. The stories told this week highlight not only the potential of new medications to change lives, but also the importance of honest dialogue about the physical and emotional realities of weight loss. Social platforms remain abuzz, but the conversation is shifting toward understanding the full spectrum of medical, ethical, and personal implications.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Zayıflama iğneleri gerçekten çözüm mü, yoksa yeni bir diyet kültürü formu mu?Bu bölümde, son yılların en popüler konularından biri olan GLP-1 iğnelerini konuşuyoruz. Ozempic, Wegovy, Mounjaro gibi isimlerle karşımıza çıkan bu ilaçlar aslında nereden çıktı, ilk başta hangi hastalıklar için geliştirildi ve nasıl oldu da “zayıflama iğnesi”ne dönüştü?Bilimsel ama sade bir dille, tokluk hissinin beyinde nasıl oluştuğunu, GLP-1 hormonunun vücuttaki rolünü, ve bu ilaçların davranışsal etkilerini ele alıyoruz.Ayrıca bir yeme bozukluğu koçu olarak bu tür müdahalelerin, özellikle geçmişinde diyet kültürüyle mücadele etmiş kişilerde hangi duygusal tetiklemeleri yaratabileceğinden de bahsediyorum.

In part 2 of this GLP-1 series, Ted shares two real-life case studies that reveal when weight loss drugs like Ozempic, Wegovy, and Mounjaro deliver results—and when they don't. Discover the surprising lessons that make the difference. If you missed part 1, go back to hear Ted break down the dos and don'ts of these drugs, how they work, the results people are seeing, and the lifestyle shifts that ensure lasting success. Listen now!  Click here for part 1:   

Millions of adults take popular drugs like Ozempic, Wegovy, and Mounjaro to treat chronic conditions and/or lose weight. The GLP-1 medications have made headlines for their effectiveness, and new studies have shown that some of them can also curb alcohol and drug consumption and lower the risk of a heart attack. But not everyone has equal access to the medications. While some patients are able to obtain them through their health care providers, others have turned to online platforms that don't require prescriptions. In many cases, they can also be cost prohibitive: Ozempic, for example, can cost up to $1,000 per month without insurance. This hour, we explore the latest with these medications: what they treat, how they work, and who should be able to access them. Our guests: Zachary Burns, D.O., assistant professor of family medicine at the University of Rochester Medical Center and associate director of Moving Medicine Forward  Erica Davis, patient who uses weight loss medication, theater professional, educator, and mother Molly Ranney, MS, RD, CDN, CSOWM, lead dietitian for the Bariatric Center at Highland Hospital Kaci Schiavone, M.D., assistant professor in the Department of Surgery, Bariatric/GI at the University of Rochester Medical Center ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

When Serena Williams shared that she lost over 30 pounds in eight months using a GLP-1 weight-loss medication, the internet lost its mind. Accusations of "cheating," debates about fairness, and endless opinions followed — but Dr. Joe says it's time we stop judging people for using proven medical tools. In this episode, Dr. Joe breaks down: ✅ Why even elite athletes struggle with weight loss ✅ The science behind GLP-1s (Ozempic, Mounjaro, etc.) ✅ Why "discipline" isn't the only answer ✅ How obesity is not a moral failure — it's a medical condition ✅ What this backlash really says about our culture and stigma If you've ever judged someone for taking a weight-loss medication — or felt judged yourself — this is a must-watch.

  In this episode, I'm joined by Claire Buckley, who opens up about her lifelong struggle with food, emotional eating, and the constant “food noise” that shaped so much of her life. Claire talks about how she first realised her relationship with food felt different from those around her, the frustration of seeking help through traditional weight loss groups, and the deeper emotional cycle that kept her feeling stuck. She shares honestly about panic attacks, shame, and the sense of failure that came with every new attempt — and how finding the right support, along with her experience using Mounjaro, has helped her quiet the noise and begin to rebuild trust with herself. It's a powerful, relatable conversation about self-awareness, compassion, and what it really means to find peace with food.

Check out my playlist!https://open.spotify.com/playlist/7J0ac0SgxZCg6aCMZgFHPp?si=Uql5G6VDSsCXl0urVAuGUAHowdy Hello and welcome to "Phat Love Talk"! I'm your host, Phat Love, and I'll be taking you on a journey through news and media I find interesting! TV Shows and Movies you should be watching, Sports conversations, Books I enjoyed reading and even some personal topics like my journey with weight loss on Mounjaro, Mental Health and living with Anxiety, Depression and ADHD. Be sure to check out my brother podcast, "AlphaPhenomenon Gaming Podcast", for all future gaming episodes. This ones for me, care to take a seat and listen?

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Weight-loss drugs like Ozempic®, Wegovy®, and Mounjaro™  or GLP-1 can reset your appetite—but only you can rewire your brain. In this episode, I'm showing you how to use your quiet-appetite season on Ozempic as a bridge, not a crutch. You'll learn how to shift from the Dieter's Mindset to the Stop Dieting Forever Mindset and build habits that actually stick while your food noise is quiet. ✨ What You'll Learn in This Episode: Why Ozempic can change your biology—but not your beliefs How to reprogram habits while your appetite is quiet The difference between the Dieter's Mindset and the Stop Dieting Forever Mindset How to apply the Four ForeverWell Essentials  A guilt-free way to enjoy treats—with grown-woman boundaries How to use self-coaching to manage stress and cravings The TikTok story that shows what happens when you skip the mindset work ====================== FEATURED ON THE SHOW / RESOURCES

According to a KFF poll, about one in eight, or 12%, of adults in the United States have used a GLP-1 medicine like Ozempic, Trulicity, Victoza, Mounjaro, Wegovy, or Zepbound. These drugs were originally developed to treat diabetes, but quickly started being prescribed for weight loss and other uses. While they seem like wonder drugs, GLP-1 medicines do cause side effects and have risks. Nausea, vomiting, diarrhea, and constipation are common side effects. The drugs also can cause dizziness, headaches, and elevated heartbeat.  Dr. Neil Iyengar is a breast medical oncologist who studies how diet and exercise can improve quality of life for people with breast cancer. He's also prescribed GLP-1 medicines for the people he cares for. Listen to the episode to hear Dr. Iyengar explain: how GLP-1 medicines work the risks these drugs may pose for people receiving chemotherapy, immunotherapy, or a CDK4/6 inhibitor why he works closely with a weight loss specialist or endocrinologist when prescribing these medicines why the medicines work best when a person also makes lifestyle changes

Are Ozempic, Wegovy, and Mounjaro really the miracle solution for weight loss? In part 1 of this 2 part series, Ted breaks down how GLP-1 drugs work, the results people are seeing and the potential downsides no one talks about. Plus, the lifestyle shifts that ensure lasting success. Listen now! 

Siquoyia Blue interviews Michelle about starting Mounjaro after a borderline diabetic A1C, the side effects she experienced (headaches, constipation, fatigue), and how she managed them. Michelle shares results—about 15 pounds lost in six weeks—advice for people who can’t exercise, thoughts on safety comparing doctor‑prescribed drugs vs. online GLP‑1s, and the importance of mental health and self‑confidence when using weight‑loss medications. Subscribe to Blu Alchemist Podcast Substack Newsletter: https://siquoyiablue.substack.com/ Podcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website: https://www.blualchemistpodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Siquoyia Blue Website: https://siquoyiablue.komi.io⁠⁠⁠⁠ YouTube: @blualchemistpodcast Buy Dating Assassins Card Game: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.datingassassins.com ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want to either be a guest on or find guests for your podcast, please sign up here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.joinpodmatch.com/siquoyia⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donate via Cashapp: @KingSiquoyia or Venmo: @KingShay Thanks for listening! Subscribe, Share and Follow us!

Can medications like Ozempic and Mounjaro actually do more than help you lose weight? This minisode features highlights from our full conversation, which premiered October 7th, 2025. Watch the full episode here → https://youtu.be/AcVIiy201H4?si=nlaFL3JnoZHxQVFh Dr. Rocio Salas-Whalen and I explore the difference between GLP-1, GIP, and triple-agonist drugs — and what's next in obesity medicine, how estrogen changes after 40 drive midsection weight gain and inflammation, why GLP-1s reduce cancer and Alzheimer's risk through anti-inflammatory and neuroprotective effects and how obesity and insulin resistance impact fertility and PCOS — and how GLP-1s can help.If you've ever wondered whether GLP-1s are just “weight loss shots” or a real step forward in metabolic and brain health — this “minisode” is a must-listen. *** Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 00:04  – The Probiotic GLP-1 Myth 00:19 – The “iPhone Evolution” of GLP-1 Drugs 00:52 – GLP-1 vs GIP vs Triple Agonists Explained 01:24 – Phase 3 Results & Massive Weight Loss Outcomes 01:38 – The Role of Glucagon in Weight Loss 01:56 – Menopause, Estrogen & Midlife Weight Gain0 3:06 – The “Fat Shift” After 40 04:01 – Can You Combine HRT and GLP-1s? 06:17 – “Willpower” vs Biology in Obesity 07:49 – The Genetic and Hereditary Roots of Obesity 08:57 – Breaking the Transgenerational Cycle 09:30 – Thyroid Cancer Myths and GLP-1 Safety 10:49 – GLP-1s and Breast Cancer Prevention 12:06 – Inflammation as the Root of Disease 12:28 – Neuroprotection and Alzheimer's Prevention 13:17 – GLP-1s, PCOS & Fertility Benefits 13:53 – The Positive Ripple Effect on Mental Health 14:21 – GLP-1s Reduce Alzheimer's Risk by 33% 14:58 – The Future of Metabolic Health Learn more about your ad choices. Visit megaphone.fm/adchoices

Girl, I am so over these creepy AI “fitness” ads. Filters are bad enough but now we have actual robots preaching toxic diet culture BS! It's wild how far we've come from Photoshop and filters — now we're literally being sold body image standards that don't even exist.In this episode, I'm venting (because seriously, what is happening?!) but also unpacking what this means for those of us healing our relationship with our bodies. Because if you're already struggling to feel good in your skin, seeing these fake “fitfluencers” can seriously mess with your head.We'll talk about: 

Drugs like Ozempic and Mounjaro were first developed to treat diabetes. They turned out to be so effective at helping people lose weight that new versions were approved for weight loss. And now, their use has skyrocketed. One in every eight American adults has taken what are known as GLP-1 drugs. They not only lead to health benefits associated with weight loss, like lower risk of heart attack and stroke, they also seem to tame addictive cravings and boost sleep. Coming up at 9 a.m. on Wednesday, MPR News guest host Catharine Richert talks with a doctor and a dietitian about the exploding popularity of GLP-1 drugs, side effects and how to use them responsibly.

Are you on a GLP-1 medication like Ozempic or Mounjaro — and wondering if there's a natural way to come off it safely? In this powerful solo episode, Shana breaks down what causes GLP-1 to become depleted, how to rebuild your body's natural production, and the exact steps she recommends for weaning off meds. You'll also hear a detailed walkthrough of her proven weaning protocol (with screen recording!), plus the lifestyle strategies and tools that support long-term metabolic healing. If you're looking for lasting freedom from weight struggles, blood sugar crashes, and medication dependency — this episode is for you.

Could GLP-1s like Ozempic and Mounjaro be making you feel less motivated? Registered Dietitians Kait Richardson and Megan Ware explore how weight loss medications impact the brain's reward (dopamine) system for better or for worse.Get your own personalized nutrition plan!Work 1:1 with Kait & Megan: ⁠⁠⁠⁠www.orlandodietitian.com⁠⁠⁠⁠Follow us on Instagram: Nutrition Awareness: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/nutrition.a..⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Our books:You can order How to Eat Like a Normal Person: A Guide to Overcoming the All-or-Nothing Mindset with Food & Diet ...on ⁠⁠⁠Amazon⁠⁠⁠⁠!And The Optimized Life ... on Amazon⁠⁠⁠ ⁠here⁠⁠⁠⁠!Speaking:Kait is available for virtual and in-person speaking events to inspire your team to stop dieting and eat healthier. Learn more on her website ⁠⁠⁠⁠www.kaitrichardsonrd.com⁠⁠⁠⁠.Disclaimer: Kait and Megan are Registered Dietitians, not licensed therapists or medical doctors. This information is for educational and entertainment purposes only. It is not meant to be a substitute for mental health counseling or medical advice.

We're going there today.Ozempic, Wegovy, Mounjaro — the weight-loss drugs everyone's talking about.But here's what no one's saying: yes, these meds work… but at what cost?In this episode, Nikkiey Stott breaks down the truth about GLP-1 weight-loss drugs, the science behind how they actually work, and the reality of what happens when you stop taking them. She dives into the research on muscle loss, metabolism slowdown, and why relying on medication alone sets so many women up for the rebound cycle they've spent years trying to escape.This isn't about fear — it's about facts.You'll walk away understanding: • Why muscle is the single most important factor in fat loss after 40 • What studies really show about GLP-1s and metabolism • The right vs. wrong way to use weight-loss meds (if you choose to) • And the exact lifestyle framework that always wins — with or without a prescriptionIf you're tired of chasing shortcuts and ready to finally understand how to create sustainable results, this episode will change the way you see your body, your health, and your power.

Inside the black market of fake and illicit versions of drugs used for weight loss like Ozempic and Mounjaro. Plus, Riverdale's Lili Reinhart explores the dark world of content moderation in new film. And the uproar over A.I. 'actress' Tilly Norwood. Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's Pop Culture Thursday, which means Jared dives into Page Six and lets the riffs fly. He breaks down the “snub or not” moment between Charlize Theron and Johnny Depp at Paris Fashion Week, then pitches the rom-com we all deserve: Lana Del Rey and her alligator wrangler husband taking on haute couture. Jared questions why Travis Kelce gets boyfriend bonus points for spending his birthday at Taylor's movie premiere and contrasts the vibes and fans of Taylor Swift versus Charli XCX amid that “actually romantic” dust-up. He talks about Amy Schumer's very public Mounjaro journey and how the internet bullies celebrities into over-explaining. Finally, he weighs in on the “very real” PDA tour of Sydney Sweeney and Scooter Braun and why people seem weirdly suspicious of her every move!Get $10 off your first month's subscription of Nutrafol & free shipping with promo code FEATHER at https://www.nutrafol.com

Can obesity, menopause, and even Alzheimer's risk be transformed with one class of medications? Triple board-certified endocrinologist Dr. Rocio Salas-Whalen joins The Neuro Experience to unpack the science behind GLP-1 therapies, sustainable weight loss, and hormone health. One of the earliest physicians to adopt GLP-1 treatments, Dr. Salas-Whalen has redefined how obesity and midlife health are managed—showing why weight gain isn't about “willpower” but biology, inflammation, and longevity. A leader in obesity and hormone medicine, Dr. Salas-Whalen founded StrengthMD and The Dry Revolution, sharing evidence-based wellness insights worldwide. Her upcoming book, Weightless: A Doctor's Guide to GLP-1 Medications, Sustainable Weight Loss, and the Health You Deserve, launches Dec 30, 2025 (U.S./Canada) and early 2026 worldwide. Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution Subscribe to The Neuro Experience for more conversations at the intersection of brain science and performance. I'm committed to bringing you evidence-based insights that you can apply to your own health journey. *** A huge thank you to my sponsors for supporting this episode. Check them out and enjoy exclusive discounts: Puori Go to https://puori.com/NEURO and use the code NEURO at checkout for 20% off. Wildgrain For a limited time, Wildgrain is offering our listeners $30 off the first box - PLUS free Croissants in every box - when you go to https://Wildgrain.com/NEURO to start your subscription.  OSEA Get 10% off your first order sitewide with code NEURO at https://OSEAMalibu.com. You'll get free samples with every order, and free shipping on orders over $50. Honeylove Save 20% Off Honeylove at https://honeylove.com/NEURO. Brickhouse Nutrition Check out the university study and get 20% off when you use promo code NEURO at https://brickhousenutrition.com. Eko Health Get $50 off, plus a FREE custom chest piece cover ($25 value) when you go to https://ekohealth.com/NEURO  *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 01:44 – Dr. Rocio's Journey into Endocrinology 02:38 – Discovering the First GLP-1 Drug 03:29 – Early Results & FDA Approval 05:00 – GLP-1 101: What It Is + How It Works 06:28 – Natural vs Synthetic GLP-1s 07:09 – GLP-1s & Alzheimer's Link 08:20 – GLP-1s vs Bariatric Surgery 09:32 – Rewiring Cravings in the Brain 11:24 – Anti-Inflammatory Benefits of GLP-1s 11:24 – Ad 15:19 – Ozempic, Mounjaro & Next-Gen GLP-1s 17:02 – GLP-1s & Women's Hormones 19:26 – Will You Be on GLP-1 Forever? 21:35 – The Myth of Willpower 23:22 – Breaking Generational Obesity Cycles 24:43 – GLP-1 & Thyroid Cancer Myth 25:55 – Ad27:55 – GLP-1s Reduce Cancer Risk 29:12 – Inflammation & GLP-1s 30:00 – GLP-1s & Fertility (PCOS) 31:27 – GLP-1 Meds Cut Dementia Risk by 33% 32:04 – Muscle Loss on GLP-1s? 33:14 – Muscle: Your Body's Anti-Inflammatory Organ 34:01 – How to Eat Enough Protein on GLP-1s 35:19 – Tracking Your Body Composition 36:57 – Build Muscle While Losing Weight 37:25 – GLP-1 Side Effects & How to Avoid Them 38:24 – The GPS Method (GLP-1 + Protein + Strength) 38:24 – Ad 41:15 – Exposing “GLP-1 Gummies” & Celeb Hype 41:34 – Microdosing & Maintenance Explained 45:01 – The Emotional Shift in Patients 46:07 – The Future of GLP-1s 48:04 – Ending Chronic Disease Learn more about your ad choices. Visit megaphone.fm/adchoices

Big Pharma has convinced millions that GLP-1 drugs like Ozempic and Mounjaro are the only way to quiet food noise and lose weight. But what if their own studies told a very different story? In this episode, Chalene unpacks shocking findings hidden in plain sight — including why some placebo groups lost weight and what that means for you. She also shares surprising natural options that research shows can help regulate hunger hormones, balance blood sugar, and reduce cravings. If you've ever wondered whether there are safer, more affordable ways to reach your goals without a lifetime prescription, this is an episode you don't want to miss. Watch this episode on YouTube this Sunday!!  https://www.youtube.com/@chalenejohnson/videos